NEW YORK, NY--(Marketwire -02\/02\/12)- TriMarkPublications.com cites in its newly published \"Companion Diagnostics in Personalized Medicine and Cancer\" report that the companion diagnostics market will explode as the personalized medicine market catapults to $42 billion by 2015. For more information, visit: http:\/\/www.trimarkpublications.com\/products\/Companion-Diagnostics-in-Personalized-Medicine-and-Cancer-Therapy.html<\/a>. <\/p>\n Companion diagnostics is the use of genetic variation (e.g., SNPs, gene expression variability and other molecular signatures) to detect different patient responses to particular drugs or biologic agents in order to understand and correlate their individual differential responses to pharmaceutical agents. Companion diagnostics can be deployed clinically to stratify patients based on their response to certain therapeutic agents, known as personalized medicine, and companion diagnostics will also play an increasingly important role in cancer treatments over the forecast period. <\/p>\n The \"Companion Diagnostics in Personalized Medicine and Cancer\" report covers: <\/p>\n Epidermal Growth Factor Receptor Assay, Individualized Warfarin Therapy and other uses of companion diagnostics in clinical situations IVDMIA, Irinotecan and UGT1A1, Tyrosine Kinase and other cancer biomarker tests MGMT Methylation Assay and other pharmacogenomics tests Recurrence prediction tests Blood-based technologies Proteomics Personalized Medicine Coalition (PMC) Health Insurance Portability and Accountability Act (HIPPA) Clinical Laboratory Improvement Amendments (CLIA) <\/p>\n The \"Companion Diagnostics in Personalized Medicine and Cancer\" report examines companies manufacturing companion diagnostics equipment and supplies in the world. Companies covered include: 20\/20 GeneSystems, Abbott, Affymetrix, Agendia, Agilent, Almac, AMDL, Applied, Asuragen, Aureon, BD, Beckman Coulter, BioCurex, Biomarker, Biomedical, Biomerica, bioM\u00e9rieux, Biomira, BioModa, Clarient, Claros, Correlogic, CytoCore, Cytogen, Dako, DiaDexus, DiagnoCure, DRG, EDP, Eisai, EXACT, Exagen, Gene Logic, Genesis, Genomic, Health Ikonisys, Illumina, Incyte, InterGenetics, Ipsogen, Johnson & Johnson, LabCorp, Life, Matritech, Miraculins, Monogram, Myriad, NimbleGen, Northwest, Nycomed, Oncotech, Oncothyreon, Orion, Oxford, Polymedco, Power3, Prometheus, Proteome, Qiagen, Roche, SensiGen, Siemens, SuperArray, Tosoh, TrimGen, Upstream, Veridex, Vermillion and Vertex. <\/p>\n Detailed charts with sales forecasts and marketshare data are included. For more information, visit: http:\/\/www.trimarkpublications.com\/products\/Companion-Diagnostics-in-Personalized-Medicine-and-Cancer-Therapy.html<\/a>. <\/p>\n About TriMarkPublications.com <\/p>\n TriMarkPublications.com is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit http:\/\/www.trimarkpublications.com<\/a>. <\/p>\n Important Notice <\/p>\n The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially. <\/p>\n<\/p>\n See the original post: NEW YORK, NY--(Marketwire -02\/02\/12)- TriMarkPublications.com cites in its newly published \"Companion Diagnostics in Personalized Medicine and Cancer\" report that the companion diagnostics market will explode as the personalized medicine market catapults to $42 billion by 2015. Continue reading
\nCompanion Diagnostics Market to Explode as Personalized Medicine Market Catapults to $42 Billion by 2015<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"